Physician profile
Sherrie L Bills
NPI 1174795884
$12,595.42
in general payments reported to CMS, 2019-2025
45 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 99% of Otorhinolaryngology & Head-Neck providers received nationally (typical 2025 total: $1,519).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,969 · 2022: $2,334 · 2023: $2,564 · 2024: $2,920 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,292.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,840.88 | 2021-2025 | |
| Lilly USA, LLC | $1,153.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,058.51 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $929.11 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $783.89 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $504.00 | 2021-2025 | |
| Amgen INC. | $502.04 | 2021-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $318.62 | 2021-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $311.19 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $310.92 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Novartis Pharmaceuticals Corporation | $257.91 | 2024-2025 | |
| Abbott Laboratories | $256.20 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $246.19 | 2022-2025 | Auvelity, Symbravo |
| Vanda Pharmaceuticals INC. | $237.24 | 2025 | Fanapt, Hetlioz |
| Dexcom, INC. | $222.25 | 2021-2025 | Dexcom G6 Transmitter |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.07 | 2021-2024 | Ofev, Jardiance |
| Sanofi-Aventis U.S. LLC | $207.17 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $172.36 | 2022-2024 | Spravato |
| Exact Sciences Corporation | $171.84 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $155.55 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.02 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $149.94 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $136.95 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.75 | 2022-2025 | Caplyta |
| Corcept Therapeutics | $127.67 | 2022-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $125.20 | 2022-2025 | Eliquis, Camzyos |
| Radius Health, INC. | $118.12 | 2023-2025 | Tymlos |
| Amarin Pharma, INC. | $87.30 | 2021-2022 | |
| Esperion Therapeutics, INC. | $86.79 | 2021-2023 | Nexletol |
| Lundbeck LLC | $83.94 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $75.81 | 2024-2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $65.14 | 2022 | |
| Phathom Pharmaceuticals, INC. | $63.19 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $58.67 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $50.31 | 2021-2024 | Yupelri |
| Inspire Medical Systems, INC. | $40.76 | 2024-2025 | Inspire |
| Insulet Corporation | $28.69 | 2024 | Omnipod |
| Currax Pharmaceuticals LLC | $28.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.60 | 2022-2025 | Zoryve |
| Medtronic, INC. | $23.36 | 2025 | Inpen Smart Insulin Delivery System |
| Seqirus USA INC | $19.31 | 2022 | |
| Corium, LLC | $18.70 | 2024 | Azstarys |
| Alexion Pharmaceuticals, INC. | $15.04 | 2022 | |
| Ibsa Pharma INC. | $13.54 | 2022 | |
| Orexo US, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrie Bills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.